Phaseline

Targets › CDH6

CDH6 (Cadherin-6): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, P55285)

Open in Phaseline: the race on CDH6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hansoh BioMedical R&D CompanyHS-20124
anti-CDH6 antibody-drug conjugate (DAR-8)
CDH6Phase 1Solid CancerDec 2026
Phrontline BiopharmaTJ102
CDH6/FRα directed antibody-drug conjugate with dual payloads
CDH6, FOLR1Phase 1Ovarian CancerSep 2029

Conditions

Ovarian Cancer (1) Solid Cancer (1)

Modalities

protein or peptide (2)

Companies

Phrontline Biopharma (1) Hansoh BioMedical R&D Company (1)

Related targets

FOLR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.